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rotein Quality
ontrol in Heart Disease
sing Established Drugs
o Target Novel Mechanisms*
rancisco Villarreal, MD, PHD,†
ilbur Y. W. Lew, MD†‡
a Jolla and San Diego, California
he heart, along with other cells in the body, requires
ontinuous protein synthesis and degradation, with pro-
ein turnover rates of approximately 2% per day. This
ynamic process is highly regulated by protein quality
ontrol systems that identify and process damaged or
isfolded proteins, which increase with stress. Misfolded
roteins are escorted by chaperones for repair or disposal
ia 2 major mechanisms. The ubiquitin-proteosome sys-
em (UPS) tags proteins with ubiquitin to identify them
or degradation by the 26S proteosome (1). Autophagy
egrades proteins and organelles by lysosomal proteases
2). When these processes are impaired or overwhelmed,
rotein aggregates can accumulate with potentially toxic
ffects.
See page 1418
Recognition of UPS as a major mechanism for degrading
roteins (awarded the Nobel Prize in chemistry in 2004) has
ccompanied an emerging appreciation for the role of
rotein quality control in disease, such as with hypoxia,
nflammation, cancer, and neurodegenerative diseases (1).
oluble proteins aggregate to form intermediates and amy-
oidogenic species that assemble into insoluble fibrils that
ccumulate in affected tissues or organs. Excessive deposits
f protein aggregates contribute to the pathogenesis in
lzheimer’s disease, Parkinson’s disease, and spongiform
ncephalopathies (prion disease) (3). Amyloidosis is a local
r systemic disease secondary to chronic inflammation,
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Cardiology Division, Department of Medicine, University of California,
an Diego, La Jolla, California, and the ‡Department of Veterans Affairs Healthcare
ystem, San Diego, California. Supported by the National Institutes of Health (grants
L-43617 and HL-80049), the Department of Veterans Affairs, and the Tobacco-p
elated Disease Research Program (16IT-0007), Office of the President, University
f California. The authors report that they have no relationships to disclose.lasma cell dyscrasias, or hereditary forms that results in
myloid deposits in different organs, including the heart (4).
Drugs that target UPS have been developed to prevent
rotein misfolding and accumulation of protein aggregates.
ortezomib, a selective proteasomal inhibitor that inhibits
PS, is the first drug in this new class to receive Food and
rug Administration approval for the treatment of multiple
yeloma. Discovery of additional drugs to inhibit abnormal
rotein aggregates would provide a significant advance
ecause there are few therapeutic options for many of these
iseases.
rotein quality control in heart disease. Abnormal pro-
ein quality control occurs in cardiac diseases, including
ypertrophy, heart failure, cardiomyopathy (5), and athero-
clerosis (6). It is still uncertain which forms of abnormal
roteins (e.g., soluble or insoluble) are toxic and if protein
ggregates are the trigger or the consequence of a given
isease process.
In this issue of the Journal, Zheng et al. (7) examined
rotein aggregation in transgenic mice with cardiac
yocyte overexpression of a mutation of B-crystallin, a
mall heat shock protein that functions as a chaperone for
esmin. Transgenic mice develop a desmin-related car-
iomyopathy with aberrant protein aggregation with
reamyloid oligomers causing intrasarcoplasmic amyloid-
sis, concentric cardiac hypertrophy, progressive heart
ailure, and increased mortality (7). This is similar to
esmin-related cardiomyopathy in humans, a family of
iseases related to mutations in desmin, B-crystallin, or
yotilin genes (8). Desmin is found in skeletal and heart
uscle and Purkinje fibers, so that desmin-related my-
pathies are associated with skeletal muscle weakness,
ilated or hypertrophic cardiomyopathy, arrhythmias,
nd conduction defects (8).
In the study by Zheng et al. (7), the protein aggregation,
ardiac hypertrophy, heart failure, and death developing in
ransgenic mice with missense mutant B-crystallin were
ttenuated with oral doxycycline (added to the drinking
ater) treatment for 4 weeks, particularly when started early
n life. Therapy started later in life (after cardiac hypertro-
hy and heart failure have developed) remains beneficial by
rolonging survival. Doxycycline inhibited protein aggrega-
ion in cardiomyocytes in vivo and in vitro, suggesting a
ovel mechanism for the cardioprotective effects. The
echanisms for doxycycline-induced decreases in misfolded
roteins and protein aggregation are not entirely clear, but
hey do not seem to involve activation of autophagy.
oxycycline may serve as a chaperone or may act at other
otential pathway sites to maintain protein quality control
Fig. 1).
etracyclines. The tetracyclines are a family of broad-
pectrum antibiotics that include tetracycline, doxycycline,
nd minocycline. They have been used safely for half a
entury and are well tolerated. The tetracyclines possess
leiotropic properties that broaden their application beyond
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Protein Quality Control in Heart Disease October 19, 2010:1427–9heir use as antibiotics (9). Tetracyclines inhibit matrix
etalloproteinases, apoptosis, and inflammation and act as
ntioxidants by scavenging reactive oxygen species. Polycy-
lic compounds inhibit the formation of abnormal protein
ggregates, which is of potential use in diseases with
mpaired protein quality control.
Tetracycline inhibits conversion of human amylin (a
ancreatic hormone cosecreted with insulin) into insoluble
myloid, which occurs in pancreatic B-cells in type 2
iabetes (10). Tetracycline inhibits misfolding of soluble
ligomers to delay development of diabetes in transgenic
ice that express human amylin/islet amyloid (11).
Tetracyclines cross the blood–brain barrier and have been
sed in neurodegenerative diseases. Minocycline prevents
he accumulation of beta-amyloid and aggregated tau pro-
eins that occur in Alzheimer’s disease models (12). Tetra-
yclines inhibit conversion of cellular prion protein into an
nsoluble species that is resistant to protease digestion and
ggregates into abnormal prions (13). Doxycycline delays
he onset of clinical disease and prolongs survival in animal
odels of prion infectivity (14).
Tetracyclines concentrate in the heart, which led to the
arly use of radiolabeled tetracyclines to identify experimen-
al myocardial infarction (15). Minocycline is lipophilic and
s taken up in the heart, particularly in ischemic myocar-
ium (24- to 50-fold higher concentrations than in blood),
here their antioxidant and matrix metalloproteinase inhib-
tory effects limit injury after myocardial ischemia-
eperfusion (16). Similar effects are observed in isolated
ardiomyocytes and fibroblasts. The ability of tetracyclines
o concentrate in injured tissues in conjunction with their
rotective properties provides targeted drug delivery without
ajor side effects.
onclusions. The discovery of disorders of protein quality
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Figure 1 Cellular Events Critical to Protein Quality Control
Illustration showing that normal and misfolded proteins can be degraded via
the ubiquitin–proteasome system. Abnormal protein aggregates are degraded
via the autophagy–lysosome system. Doxycycline (DOXY) may intervene in key
steps to shift the balance to decrease misfolded and abnormally aggregated
proteins.ontrol as a mechanism for disease has led to novel thera-eutic targets with the development of a new class of drugs,
uch as the protease inhibitor bortezomib. Existing drugs
uch as the tetracycline family of antibiotics may have
imilar effects with several potential advantages. Tetracy-
lines have been used for half a century with proven safety
nd tolerance, cross the blood–brain barrier, concentrate in
he heart, and have anti-inflammatory and antioxidant
ffects that may limit the formation and toxicity of protein
ggregates.
Additional investigations are needed to establish the
ausality and unique role of protein quality control in each
isease to determine when this is a relevant target. If
isfolded proteins and protein aggregation occur second-
rily, then inhibiting this process will prevent secondary
oxic or structural effects, but will not treat the primary cause
f disease. It will be valuable to determine if chronic
ownstream changes, such as the deposition of insoluble
rotein aggregates, can be reversed by inhibiting upstream
vents such as the formation of misfolded proteins. Char-
cterizing conditions where protein quality control plays a
ajor role will provide a more rational approach for the
uccessful clinical translation of targeting this unique ther-
peutic site.
Another challenge for clinical translation will be to define
he mechanisms for tetracyclines to inhibit protein misfold-
ng and accumulation of protein aggregates. This would
etermine if these agents can be used in other diseases with
bnormal protein quality control. This would broaden
ignificantly the options to treat diseases with safe drugs for
hich few effective treatments are available.
eprint requests and correspondence: Dr. Wilbur Y. W. Lew,
ardiology Section 111A, Department of Medicine, Veterans
ffairs San Diego Healthcare System, University of California–
an Diego, San Diego, California 92161. E-mail: wlew@ucsd.edu.
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